公开(公告)号：US20200216515A1

公开(公告)日：2020-07-09

申请号：US16633604

申请日：2018-07-26

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Anne-Sophie GAUTRON ,  Laurent POIROT

IPC: C07K14/725 ,  C12N15/10

Abstract: The present disclosure provides in vitro and in vivo methods for selecting a candidate CAR polynucleotide to be expressed in immune cells for its preferential capability to make immune cells proliferate in an antigen-dependent manner.

公开(公告)号：US20200149056A1

公开(公告)日：2020-05-14

申请号：US16719544

申请日：2019-12-18

Applicant: CELLECTIS

Inventor： Luc Mathis ,  Zachary Demorest ,  Feng Zhang ,  William Haun

IPC: C12N15/82 ,  A01H5/10 ,  A23D9/00 ,  A01H1/06 ,  A01H6/54

Abstract: Materials and methods are provided for making soybean varieties that have altered oil composition as a result of mutations in the FAD3A, FAD3B, and FAD3C genes.

公开(公告)号：US20200048648A1

公开(公告)日：2020-02-13

申请号：US16608060

申请日：2018-04-25

Applicant: CELLECTIS

Inventor： Song Luo ,  Nicholas J. Baltes

IPC: C12N15/82

Abstract: Materials and methods for creating plants (e.g., alfalfa lines) with reduced lignin content and composition are provided herein, as are plants, plant parts, and plant cells generated by the methods provided herein.

公开(公告)号：US10544201B2

公开(公告)日：2020-01-28

申请号：US15329530

申请日：2015-07-29

Applicant: CELLECTIS

Inventor： Cècile Schiffer-Mannioui

IPC: C07K14/705 ,  C07K14/735 ,  C07K16/28

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen ROR1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen ROR1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially chronic lymphocytic leukemia or solid tumors.

公开(公告)号：US20200002709A1

公开(公告)日：2020-01-02

申请号：US16328323

申请日：2017-08-30

Applicant: CELLECTIS

Inventor： Song Luo ,  Benjamin Clasen ,  Feng Zhang ,  Nicholas J. Baltes ,  Javier Gil Humanes

IPC: C12N15/82

Abstract: Materials and methods are provided for making plants (e.g., soybean varieties, wheat varieties, or corn varieties) with altered amino acid content. For example, materials and methods are provided for making TALE nuclease-induced mutations in genes encoding seed storage proteins, or by making TALE nuclease-induced deletions of within seed storage protein genes.

公开(公告)号：US10426795B2

公开(公告)日：2019-10-01

申请号：US14403937

申请日：2013-05-13

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: C12N5/10 ,  A61K38/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20190211349A1

公开(公告)日：2019-07-11

申请号：US16326549

申请日：2017-08-18

Applicant: CELLECTIS

Inventor： Benjamin Clasen ,  Song Luo ,  Daniel F. Voytas ,  Feng Zhang

IPC: C12N15/82 ,  C12N15/52

CPC classification number: C12N15/8261 ,  C12N9/0059 ,  C12N15/52 ,  C12N15/8242 ,  C12Y110/03001

Abstract: Materials and methods are provided for making plants (e.g., Solanum varieties) with resistance to black-spot bruising, specifically, by making TALE-nuclease-induced mutations in genes encoding tuber specific expressed polyphenol oxidase.

公开(公告)号：US10342829B2

公开(公告)日：2019-07-09

申请号：US14018021

申请日：2013-09-04

Applicant: CELLECTIS

Inventor： Julianne Smith ,  Andrew Scharenberg ,  Cecile Mannioui ,  Justin Eyquem

IPC: A61K35/17 ,  A61K38/00 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs. Such CARs, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. 91The signaling domains are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10196608B2

公开(公告)日：2019-02-05

申请号：US15120060

申请日：2015-02-20

Applicant: CELLECTIS

Inventor： Laurent Poirot ,  Philippe Duchateau

IPC: C12N9/16 ,  A61K35/17 ,  C07K14/47 ,  C07K16/28 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783

Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are designed to express both a Chimeric Antigen Receptor (CAR) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory T-cells (Treg). Preferably, such secreted inhibitor is a peptide inhibitor of forkhead/winged helix transcription factor 3 (FoxP3), a specific factor involved into the differentiation of T-cells into regulatory T-cells. The engineered T-cells of the invention direct their immune activity towards specific malignant or infected cells, while at the same time will prevent neighboring regulatory T-cells from modulating the immune response. The invention opens the way to standard and affordable adoptive immunotherapy strategies, especially for treating or preventing cancer, and bacterial or viral infections.

公开(公告)号：US20190032088A1

公开(公告)日：2019-01-31

申请号：US16073778

申请日：2017-02-24

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Veronique ZENNOU

IPC: C12N15/88 ,  A61K9/00 ,  C12N9/22 ,  C12N15/11 ,  A61K48/00 ,  A61K9/127

Abstract: The invention pertains to therapies that require gene editing, and more specifically to non-viral methods for in vivo delivery of endonuclease reagents to specific tissues or cells. According to the invention, the endonuclease reagents are encapsulated into micelle structures of 50 to 150 nm diameter for intravenous injection. The invention thus provides therapeutic composition including such micelles structures, by which endonuclease reagents can be released into cell under RNA form for their use in the treatment of gene related diseases.